<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app18.us.archive.org';v.server_ms=1705;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml', '20171002225723')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171002225723/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171002225723/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171002225723" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930194220/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 22:57:23 Oct 02, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930194220/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml" title="19:42:20 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 22:57:23 Oct 02, 2017">02</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930194220/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 22:57:23 Oct 02, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171002225723*/https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 02 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10372?contentType=xml","2017-10-02",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Bone health in patients with breast cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Breast Tumour Team. Bone health in patients with breast cancer. Edmonton (Alberta): CancerControl Alberta; 2012 Nov. 22 p.&amp;nbsp;(Clinical practice guideline; no. BR-010).&amp;nbsp; [79 references]</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Patients with Metastatic Breast Cancer</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li><strong>When to use bone-modifying agents (BMAs)</strong>. In patients with metastatic breast cancer, BMAs are recommended upon confirmation of bone metastases; the presence of non-bone metastases is not an indication for the use of BMAs. </li>
    <li><strong>Which BMAs to consider and for how long</strong>.
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>For patients with breast cancer with bone metastases, no recommendations can be made favoring one agent over another. Acceptable agents and dosing regimens for bone metastases include:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Zoledronic acid: intravenous (IV) 4 mg over no less than 15 minutes, monthly </li>
            <li>Pamidronate: IV 90 mg over no less than two hours, monthly </li>
            <li>Clodronate: oral 1600 mg, daily </li>
            <li>Denosumab: subcutaneous (SC) 120 mg, monthly </li>
        </ul>
        <p><strong>Note</strong>: There are advantages and limitations to the different agents and routes of administration. The agent and route of administration should be left to the discretion of the treating physician, taking into account compliance with treatment, cost of treatment, and patient preference.</p>
        </li>
        <li>BMAs should be continued in patients with breast cancer with bone metastases until there is evidence of a substantial decline in performance status. </li>
    </ul>
    </li>
    <li><strong>What to do after a skeletal-related event (SRE) or disease progression in bone</strong>. In patients with breast cancer with bone metastases, who have experienced an SRE or progression in bone metastases, switching from one BMA to another is currently not recommended, as there is no double-blind data to support this strategy. </li>
</ol>
<p><strong>Patients with Early Stage Breast Cancer</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;>
    <li><strong>Fracture risk assessment and timing</strong>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Baseline bone mineral density (BMD) testing and fracture risk assessment is recommended for patients with early stage breast cancer for whom therapy with agents that suppress ovarian function is planned, including:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Premenopausal women with premature ovarian failure or ovarian suppression with luteinizing hormone releasing hormone analogue (LHRHA) </li>
            <li>Postmenopausal women on aromatase inhibitors (AIs) </li>
        </ul>
        </li>
        <li>BMD testing in other postmenopausal women with early stage breast cancer is recommended according to the indications provided in the table below (Papaioannou et al., 2010). </li>
        <li>BMD is calculated using a dual-energy x-ray absorptiometry (DEXA) scan. </li>
        <li>Fracture risk should be assessed using the World Health Organization Fracture Risk Assessment Tool (FRAX; <a href=&quot;http://www.shef.ac.uk/FRAX/tool.jsp?locationValue=9&quot; title=&quot;FRAX Tool Web site&quot;>www.shef.ac.uk/FRAX/tool.jsp?locationValue=9</a>). (See <a href=&quot;http://www.who.int/bulletin/volumes/94/12/16-188532.pdf&quot; title=&quot;WHO Web site&quot;>Clarifying WHO's position on the FRAX tool for fracture prediction</a>.) </li>
        <li>Repeat BMD testing should be performed as follows, in patients for whom pharmacotherapy with BMAs is deemed to be not beneficial:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Low risk patients (10-year risk &amp;lt;10% based on FRAX score): every five years </li>
            <li>Moderate risk patients (10-year risk 10%&amp;ndash;20% based on FRAX score): every one to three years </li>
        </ul>
        </li>
    </ul>
    </li>
</ol>
<p><strong>Table. Canadian Guidelines on the Screening of Osteoporosis</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Canadian Guidelines on the Screening of Osteoporosis&quot;>
    <thead>
        <tr>
            <th valign=&quot;top&quot; colspan=&quot;2&quot;>Indications for Measuring Bone Mineral Density</th>
        </tr>
        <tr>
            <td valign=&quot;top&quot;><em>Older Adults (Age &amp;ge;50 Years)</em></td>
            <td valign=&quot;top&quot;><em>Younger Adults (Age &amp;lt;50 Years)</em></td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Age &amp;ge;65 yr (both women and men)</td>
            <td valign=&quot;top&quot;>Fragility fracture</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Clinical risk factors for fracture (menopausal women, men age 50&amp;ndash;64 years)</td>
            <td valign=&quot;top&quot;>Prolonged use of glucocorticoids*</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Fragility fracture after age 40 years</td>
            <td valign=&quot;top&quot;>Use of other high-risk medications&amp;dagger;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Prolonged use of glucocorticoids*</td>
            <td valign=&quot;top&quot;>Hypogonadism or premature menopause (age &amp;lt;45 years)</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Use of other high-risk medications&amp;dagger;</td>
            <td valign=&quot;top&quot;>Malabsorption syndrome</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Parental hip fracture</td>
            <td valign=&quot;top&quot;>Primary hyperparathyroidism</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Vertebral fracture or osteopenia identified on radiography</td>
            <td valign=&quot;top&quot;>Other disorders strongly associated with rapid bone loss and/or fracture</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Current smoking</td>
            <td valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>High alcohol intake</td>
            <td valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Low body weight (&amp;lt;60 kg) or major weight loss (&amp;gt;10% of body weight at age 25 years)</td>
            <td valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Rheumatoid arthritis</td>
            <td valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Other disorders strongly associated with osteoporosis</td>
            <td valign=&quot;top&quot;>&amp;nbsp;</td>
        </tr>
    </thead>
    <tbody>
    </tbody>
</table>
<p class=&quot;Note&quot;>Reproduced with permission from: Papaioannou A, Morin S, Cheung Am, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J. 2010; 182:1864-1873.</p>
<p class=&quot;Note&quot;>*At least three months cumulative therapy in the previous year at a prednisone-equivalent dose &amp;ge;7.5 mg daily.</p>
<p class=&quot;Note&quot;>&amp;dagger;For example, aromatase inhibitors or androgen deprivation therapy.</p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;>
    <li><strong>When to use BMAs, which agents to consider, and for how long</strong>
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>BMAs should be considered for the following patients with early stage breast cancer:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Premenopausal OR postmenopausal at high risk (i.e., 10-year fracture risk &amp;gt;20% OR prior fragility fracture of hip or spine OR more than 1 fragility fracture) </li>
            <li>Postmenopausal at moderate risk (i.e., 10-year fracture risk 10%&amp;ndash;20%) OR a T-score less than -2.0 AND undergoing aromatase inhibitor therapy for breast cancer </li>
        </ul>
        </li>
        <li>As per the Canadian Osteoporosis guidelines (Papaioannou et al., 2010), exercise, adequate calcium (1,200 mg per day total, diet plus supplements) intake, and vitamin D (1,000 IU per day) supplementation are also recommended. </li>
        <li>For patients with early stage breast cancer, no recommendations can be made favoring one BMA over another. Acceptable agents and dosing regimens for bone loss include:
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>Zoledronic acid: IV 4 mg over no less than 15 minutes every 6 to 12 months </li>
            <li>Any oral bisphosphonate </li>
            <li>Denosumab: SC 60 mg every 6&amp;ndash;12 months </li>
        </ul>
        <p><strong>Note</strong>: The route of administration should be left to the discretion of the treating physician, taking into account compliance with treatment, cost of treatment, and patient preference.</p>
        <ul style=&quot;list-style-type: disc;&quot;>
            <li>There is no data on the optimal duration of therapy with BMAs for patients with early stage breast cancer with treatment-related bone loss. Most randomized controlled trials have used durations of&amp;nbsp;2&amp;ndash;3 years and none have compared one time period with another. </li>
            <li>In patients with early stage breast cancer, there is no data to support a switch from one agent to another, following a skeletal-related event. </li>
        </ul>
        </li>
    </ul>
    </li>
    <li><strong>Monitoring for effectiveness</strong>. In patients with early stage breast cancer undergoing therapy with a BMA, BMD can be checked every two years. However, in patients with osteopenia, BMD should be checked annually. </li>
    <li><strong>Use of BMAs as adjuvant therapy</strong>. Outside of a clinical trial, BMAs are not recommended, for patients with early stage breast cancer, as a standard adjuvant therapy to improve recurrence or survival rates. </li>
</ol>
<p><strong>Patients with Metastatic or Early Stage Breast Cancer</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;>
    <li><strong>Monitoring of adverse events</strong>. Patients undergoing therapy with BMAs should be aware that the most common adverse events include nausea, fatigue, arthralgia, back pain, pyrexia, bone pain, vomiting, anemia, diarrhea, dyspnea, extremity pain, and constipation (see Table 2 in the original guideline document).
    <p>Patients should also be monitored for changes in renal function (i.e., creatinine clearance). In addition, patients with poor dental hygiene or poor dental health may be at increased risk of osteonecrosis of the jaw and should ideally consider undergoing preventive dentistry before starting treatment with a BMA. Adverse events should be managed with appropriate supportive care.</p>
    </li>
</ol></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An algorithm titled &quot;Algorithm for the Use of Bone Modifying Agents in Patients with Breast Cancer with Bone Metastases or Treatment-induced Bone Loss&quot; is provided in the original guideline document.</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Metastatic breast cancer (bone metastases) </li>
    <li>Early-stage breast cancer </li>
    <li>Bone loss and symptoms of bone loss (treatment-related or cancer-related) </li>
</ul>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Management"/>
      <fieldvalue value="Prevention"/>
      <fieldvalue value="Risk Assessment"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Endocrinology"/>
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Radiation Oncology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To provide evidence-based strategies for the management of bone loss and symptoms of bone loss in patients with a breast cancer diagnosis</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients who have been diagnosed with breast cancer and in whom bone metastases have been confirmed or those at risk of therapy-induced bone loss</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Bone-modifying agents (BMAs)
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Zoledronic acid </li>
        <li>Pamidronate </li>
        <li>Clodronate </li>
        <li>Denosumab </li>
    </ul>
    </li>
    <li>Fracture risk assessment and bone mineral density (BMD) testing </li>
    <li>Exercise, adequate calcium&amp;nbsp;intake, and vitamin D supplementation </li>
    <li>Monitoring therapy for effectiveness and adverse events </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Bone mineral density (BMD) </li>
    <li>Bone turnover </li>
    <li>Fracture rates </li>
    <li>Survival (disease-free, relapse-free, and overall) </li>
    <li>Recurrence rates </li>
    <li>Skeletal-related events (SREs) </li>
    <li>Adverse events associated with therapy </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>Research Questions</span></strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (patient or population, intervention, comparisons, outcomes).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Guideline Questions</span></strong></p>
<p><strong>Patients with Metastatic Breast Cancer</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>When should bone-modifying agents (BMAs) be used in patients with metastatic breast cancer? </li>
    <li>Which BMAs should be considered and for how long? </li>
    <li>Should the BMA be switched after a skeletal-related event (SRE) or documentation of disease progression in bone? </li>
</ol>
<p><strong>Patients with Early Stage Breast Cancer</strong><em> </em></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;>
    <li>How should fracture risk be assessed and when for:
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Premenopausal women with premature ovarian failure or ovarian suppression with luteinizing hormone releasing hormone analogue (LHRHA) </li>
        <li>Postmenopausal women on aromatase inhibitors (AIs) </li>
        <li>Other postmenopausal women with early stage breast cancer </li>
    </ul>
    </li>
    <li>Is there a role for BMAs in these populations and, if so, which agents should be considered and for how long? </li>
    <li>How should treatment with BMAs be monitored for effectiveness? </li>
    <li>Should BMAs be used as adjuvant therapy to improve breast cancer-related outcomes? </li>
</ol>
<p><strong>Patients with Metastatic or Early Stage Breast Cancer</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;>
    <li>When using BMAs, what potential adverse events should be disclosed to patients? What is the frequency of these adverse events with the different agents and schedules of administration? How should these adverse events be managed? </li>
</ol>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Search Strategy</span></strong></p>
<p>A systematic search for relevant literature related to breast cancer and bone health was conducted of: MEDLINE (1950 to 2011 July) and EMBASE (1980 to 2012 July). The search included the terms <em>zoledronic acid</em> or <em>zoledronate</em> or <em>clodronate</em> or <em>clodronic acid</em> or <em>alendronate</em> or <em>alendronic acid</em> or <em>pamidronate</em> or <em>pamidronic acid</em> or <em>ibandronate</em> or <em>ibandronic acid</em> or <em>denosumab</em> and <em>breast neoplasm</em>. The MEDLINE and EMBASE search was limited to clinical trials, phase III, randomized controlled trials, and meta-analyses published in the English language.</p>
<p>Studies that were published prior to 1996 were excluded from the evidence tables. A total of 28 clinical trials were deemed relevant to the role of bisphosphonates and denosumab in the prevention of skeletal related events in patients with metastatic breast cancer; 11 clinical trials were deemed relevant to the role of bisphosphonates or denosumab in preventing recurrence or prolonging survival in metastatic breast cancer; and 21 clinical trials were deemed relevant to the role of bisphosphonates or denosumab for the treatment of hypercalcemia of malignancy in metastatic breast cancer.</p>
<p>In addition, the National Guideline Clearinghouse was searched for guidelines and systematic reviews related to breast cancer and bone health. A total of seven clinical practice guidelines that provided recommendations on the use of bisphosphonates in the setting of breast cancer were deemed relevant; these guidelines were developed by: the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), Cancer Care Ontario (CCO), the British Columbia Cancer Agency (BCCA), the International Society of Geriatric Oncology (ISGO), the European Expert Panel (EEP), and Cancer Australia. Following the initial literature search, an additional Canadian guideline, BONUS 6, was published by a panel of experts in the field and ASCO released an updated version of their guideline.</p></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>A total of 28 clinical trials were deemed relevant to the role of bisphosphonates and denosumab in the prevention of skeletal related events in patients with metastatic breast cancer; 11 clinical trials were deemed relevant to the role of bisphosphonates or denosumab in preventing recurrence or prolonging survival in metastatic breast cancer; and 21 clinical trials were deemed relevant to the role of bisphosphonates or denosumab for the treatment of hypercalcemia of malignancy in metastatic breast cancer. </li>
    <li>A total of seven clinical practice guidelines that provided recommendations on the use of bisphosphonates in the setting of breast cancer were deemed relevant. </li>
</ul>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Not stated"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Review of Published Meta-Analyses"/>
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Breast Tumour Team and a Knowledge Management (KM) specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Guideline Utilization Resource Unit Handbook</a> (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href=&quot;http://www.agreetrust.org&quot; title=&quot;AGREE Trust Web site&quot;>http://www.agreetrust.org</a>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was drafted by a medical oncologist with expertise in the area of bone health and breast cancer, with support from a Knowledge Management (KM) specialist. An expert panel consisting of medical oncologists, radiation oncologists, breast surgeons, and pathologists then reviewed the guideline and came to consensus on the recommendations.</p>
<p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulated the guideline recommendations based on the evidence synthesized by the KM Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Guideline Utilization Resource Unit Handbook</a> (see the &quot;Availability of Companion Documents&quot; field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The guideline developers reviewed published cost analyses.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="Internal Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This guideline was reviewed and endorsed by the Alberta Provincial Breast Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="98" ordby="605" id="425" name="References Supporting the Recommendations" type="citation">
      <fieldvalue value="<table><tr><td>Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010 Nov 23;182(17):1864-73. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20940232&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Optimization of bone health in patients with breast cancer</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Adverse events associated with bisphosphonate use (oral or intravenous) and denosumab are typically mild and manageable, but include arthralgia, fever, thrombosis, bone pain, fatigue/tiredness, nausea, and gastrointestinal symptoms. The frequencies of the most common adverse events is provided in Table 2 in the original guideline document. Patients undergoing therapy with bone modifying agents should be monitored throughout therapy for changes in renal function (i.e., creatinine clearance). In addition, patients with poor dental hygiene or poor dental health may be at increased risk of osteonecrosis of the jaw; therefore, patients should consider undergoing preventive dentistry before starting treatment with a bone modifying agent and avoid extensive dental work during therapy.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services Web site. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Clinical Algorithm"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Alberta Provincial Breast Tumour Team. Bone health in patients with breast cancer. Edmonton (Alberta): CancerControl Alberta; 2012 Nov. 22 p.&amp;nbsp;(Clinical practice guideline; no. BR-010).&amp;nbsp; [79 references]</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2012 Nov"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="CancerControl Alberta - State/Local Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>CancerControl Alberta</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Alberta Provincial Breast Tumour Team</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Members of the Alberta Provincial Breast Tumour Team include medical oncologists, radiation oncologists, surgeons, pathologists, psychosocial oncologists, nurses, and pharmacists.</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Participation of members of the Alberta Provincial Breast Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Breast Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-br010-bone-modifying-agents.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. Electronic copies: Available from the <a href=&quot;http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-utilization-handbook.pdf&quot; title=&quot;Alberta Health Services Web site&quot;>Alberta Health Services Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None available</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on August 12, 2014. The information was verified by the guideline developer on September 22, 2014.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 22:57:23 Oct 02, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:10:14 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 881.247 (3)
  esindex: 0.011
  captures_list: 901.054
  CDXLines.iter: 14.275 (3)
  PetaboxLoader3.datanode: 929.265 (4)
  exclusion.robots: 0.546
  exclusion.robots.policy: 0.524
  RedisCDXSource: 0.706
  PetaboxLoader3.resolve: 658.305
  load_resource: 736.801
-->